Polymorphisms of IL-4 and IL-4R are associated to some demographic characteristics of differentiated thyroid cancer patients but are not determinants of risk in the Brazilian population

Author(s)

Martins, Mariana Bonjiorno ^[1] ; de Assis Batista, Fernando ^[1] ; Bufalo, Natassia Elena ^[1] ; Peres, Karina Colombera ^[1] ; Meneghetti, Murilo ^[1] ; da Assumpcao, Ligia Vera Montali ^[2] ; Ward, Laura Sterian ^[1]

Affiliation

^[1] Univ Campinas Unicamp, Sch Med Sci, Lab Canc Mol Genet, FCM, 126 Tessalia Vieira de Camargo St, Campinas, SP - Brazil

^[2] Univ Campinas Unicamp, Fac Med Sci, Dept Med, Div Endocrinol, 251 Vital Brazil St, Campinas, SP - Brazil

• Document type: Journal article
• Source: ENDOCRINE; v. 72, n. 2 SEP 2020.
• Web of Science Citations: 0

Abstract

Background IL-4 is known to present abnormal expression in thyroid tumors and SNPs in theIL-4and its receptorIL-4Rgenes are associated to risk and mortality of various types of cancer. Methods In order to evaluate their role in differentiated thyroid cancer (DTC), we investigated genetic frequencies of twoIL-4promoter SNPs (rs2070874 C>T, rs2243250 C>T) and four non-synonymous SNPs of theIL-4Rgene (rs1805010 A>G, rs1805012 C>T, rs1805013 C>T, rs1801275 A>G) in 300 DTC patients matched to 300 controls. All patients were managed according to current guidelines and followed-up for a period of 12-252 months (69.20 +/- 52.70 months). Results Although none of the six investigated SNPs showed association with risk of DTC, rs1805010 was associated with age of diagnosis and the SNPs rs1805012 and rs1801275 were associated to gender. Further, in-silico analysis showed that all these three SNPs were able to cause decreased stability of the protein. We were not able to demonstrate any other association to clinical features of aggressiveness or to patients' prognosis. Conclusions These findings indicate that although genetic variants inIL-4andIL-4Rdo not influence the risk or outcome of DTC patients, their influence on the behavior of thyroid tumors deserves further investigation. (AU)

• FAPESP's process: 12/16830-0 - ANALYSIS OF SERUM INTERLEUKINS IL-2, IL-4, IL-4R (RECEPTOR), IL-6, IL-6R (RECEPTOR), IL-8, IL-10, IL-12 (A,B) IN THE CLINICOPATHOLOGICAL PROFILE OF DIFFERENTIATED THYROID CARCINOMA.
• Grantee: Mariana Bonjiorno Martins
• Support Opportunities: Scholarships in Brazil - Doctorate
• FAPESP's process: 12/22726-0 - Analysis of pro-inflammatory interleukins (IL-2, IL-2R, IL-6, IL-6R, IL-8, IL-12 A and B) and anti-inflammatory (IL-4, IL-4R, IL-10) in the differentiated thyroid carcinoma
• Grantee: Laura Sterian
• Support Opportunities: Regular Research Grants